Hereditary site-specific ovarian cancer syndrome
MONDO:0016249Ovarian cancer caused by germline mutations in various genes, usually associated with additional cancer risks. The most common are breast and ovarian cancer syndrome (HBOC) due to mutations in BRCA1 and BRCA2 genes and hereditary nonpolyposis colorectal cancer (HNPCC) due to mutations in DNA mismatch-repair genes. Mutations in STK11 gene, causing Peutz-Jeghers syndrome, are also associated with a risk of ovarian cancer (typically sex cord stromal tumors). Mutations in other genes, including RAD51C, RAD51D, PALB2, confer an elevated ovarian cancer risk in a minority of patients.
2845 clinical trials for this condition and its sub-types, 2 tagged with Hereditary site-specific ovarian cancer syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug shows promise in shrinking ovarian tumors before surgery
Disease control OngoingThis early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy…
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Family genetic testing could prevent ovarian cancer
Knowledge-focused OngoingThis study looks at whether offering genetic testing to family members of people with hereditary breast and ovarian cancer syndrome helps more relatives learn about their own cancer risk. Researchers will follow 118 participants and their relatives to see how many choose to get t…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC